Harvard Bioscience reports Q4 revenue of $23.7M, outlines growth strategy

Harvard Bioscience Inc. (NASDAQ: HBIO) announced preliminary fourth quarter 2025 financial results that exceeded the midpoint of its guidance range, according to a company statement.

The life science research tools company reported preliminary revenue of $23.7 million for the quarter ended December 31, 2025, above the midpoint of its $22.5 million to $24.5 million guidance range. Gross margin reached 60%, at the high end of the company's 58% to 60% guidance range.

Adjusted EBITDA totaled $3.8 million, representing 27% growth compared to the same period last year. The company attributed the improvement to cost reductions, improved expense management and execution.

Harvard Bioscience outlined a strategic focus on four areas: leading translational bridge research, developing new product introduction pipelines, expanding consumables revenue, and operational excellence. The company currently generates 55% of total revenues from recurring revenue sources.

"We're pleased with our fourth quarter performance and excited to share an overview of our go-forward strategy," said Chief Executive Officer John Duke. "We are excited for what's ahead and are confident we will drive year over year revenue growth and mid-to high-single digit adjusted EBITDA growth in 2026."

The company expects year-over-year revenue growth and mid-to-high single-digit EBITDA growth in 2026. Harvard Bioscience plans to release complete fourth quarter and fiscal year 2025 results on March 12, 2026, followed by a conference call at 8:00 a.m. ET.

The Holliston, Massachusetts-based company develops and manufactures technologies for life science applications including research, drug discovery and preclinical testing.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Albany International ends strategic review, keeps Salt Lake City facility
• aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept